var data={"title":"Tenofovir disoproxil fumarate and emtricitabine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tenofovir disoproxil fumarate and emtricitabine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6099?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">see &quot;Tenofovir disoproxil fumarate and emtricitabine: Drug information&quot;</a> and <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tenofovir disoproxil fumarate and emtricitabine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708729\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Posttreatment acute exacerbation of hepatitis B:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Emtricitabine/tenofovir disoproxil fumarate is not approved for the treatment of chronic hepatitis B virus (HBV) infection, and the safety and efficacy have not been established in patients coinfected with HBV and HIV-1. Severe, acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued therapy. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who are infected with HBV and discontinue emtricitabine/tenofovir disoproxil fumarate. If appropriate, initiation of antihepatitis B therapy may be warranted.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of drug resistance with use for preexposure prophylaxis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Emtricitabine/tenofovir disoproxil fumarate for a preexposure prophylaxis indication must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and periodically (at least every 3 months) during use. Drug-resistant HIV-1 variants have been identified with use for a preexposure prophylaxis indication following undetected acute HIV-1 infection. Do not initiate for a preexposure prophylaxis indication if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164681\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Truvada</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934286\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Truvada</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010698\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nucleoside Reverse Transcriptase Inhibitor (NRTI)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nucleotide Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010720\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">see &quot;Tenofovir disoproxil fumarate and emtricitabine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents. <b>Note:</b> Multiple tablet strengths exist and contain different amounts of emtricitabine and tenofovir.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents weighing &ge;17 kg and who are able to swallow a tablet whole:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;17 kg: Not intended for use; product is a fixed-dose combination; safety and efficacy have not been established in these patients </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">17 to &lt;22 kg:  Oral: One tablet (emtricitabine 100 mg/tenofovir 150 mg) once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">22 to &lt;28 kg: Oral: One tablet (emtricitabine 133 mg/tenofovir 200 mg) once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">28 to &lt;35 kg: Oral: One tablet (emtricitabine 167 mg/tenofovir 250 mg) once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;35 kg: Oral: One tablet (emtricitabine 200 mg/tenofovir 300 mg)  once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis (nPEP)</b> (HHS [nPEP] 2016): Adolescents: Oral: One tablet (emtricitabine 200 mg/tenofovir 300 mg) once daily for 28 days in combination with other antiretroviral agents. Initiate therapy within 72 hours of exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b> Oral: One tablet tablet (200 mg emtricitabine/300 mg tenofovir) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pre-exposure prophylaxis (PrEP) for prevention of HIV infection in uninfected high-risk individuals:</b> Oral: One tablet (200 mg emtricitabine/300 mg tenofovir) once daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Dosing adjustment in renal impairment: Note:</b> Closely monitor clinical response and renal function in these patients; clinical effectiveness and safety of these guidelines have not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: CrCl &lt;30 mL/minute or patients requiring hemodialysis: Use not recommended (HHS [pediatric] 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 49 mL/minute: Administer every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute or patients requiring hemodialysis: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pre-exposure prophylaxis (PrEP):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;60 mL/minute: No adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;60 mL/minute: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, no dosing adjustments are necessary for tenofovir in hepatic impairment. No specific data is available on emtricitabine in hepatic impairment, but given its limited hepatic metabolism, the impact of liver impairment should be minimal; need for dose adjustment is unlikely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164669\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Truvada: Emtricitabine 100 mg and tenofovir disoproxil fumarate 150 mg, Emtricitabine 133 mg and tenofovir disoproxil fumarate 200 mg, Emtricitabine 167 mg and tenofovir disoproxil fumarate 250 mg, Emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg [contains fd&amp;c blue #2 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164659\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14633101\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021752s053lbl.pdf#page=42&amp;token=MXTHlzu2f6jTWWasC0z83GlauuwpjRMSh+XN8bb/eEd2RzfYuUtrKSGX9qipCE/r0ewLn2DUVjjBc37+5ZO1h4VQWAp0YLPXNuIrB1//ojt8LVkznSiy3+9Q5imQOUko&amp;TOPIC_ID=13013\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021752s053lbl.pdf#page=42</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010725\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to food </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164678\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store tablets at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense only in original container.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010699\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in pediatric patients [age not specified] weighing at least 17 kg and adults); <b>Note:</b> HIV regimens consisting of <b>three</b> antiretroviral agents are strongly recommended; preexposure prophylaxis (PrEP) in combination with safer sex practices for prevention of HIV infection in adults at high risk (FDA approved in adults); has also been used for HIV-1 nonoccupational postexposure prophylaxis (nPEP). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708023\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164699\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164674\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As preexposure prophylaxis in patients with unknown or HIV-1 positive status; for HIV-1 treatment, use only in HIV-1-infected patients in combination with other antiretrovirals</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity emtricitabine, tenofovir, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164661\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone mineral density: In clinical trials, tenofovir disoproxil fumarate has been associated with decreases in bone mineral density in HIV-1 infected adults and increases in bone metabolism markers. Serum parathyroid hormone and 1,25 vitamin D levels were also higher. Decreases in bone mineral density have also been observed in clinical trials of HIV-1 infected pediatric patients. Observations in chronic hepatitis B infected pediatric patients (aged 12-18 years) were similar. In all pediatric clinical trials, skeletal growth (height) appears unaffected. Consider monitoring of bone density in adult and pediatric patients with a history of pathologic fractures or with other risk factors for bone loss or osteoporosis. Consider calcium and vitamin D supplementation for all patients; effect of supplementation has not been studied but may be beneficial. Long-term bone health and fracture risk unknown. If abnormalities are suspected, expert assessment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with use of nucleoside analogues, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteomalacia and renal dysfunction: May cause osteomalacia with proximal renal tubulopathy. Bone pain, extremity pain, fractures, arthralgias, weakness and muscle pain have been reported. In patients at risk for renal dysfunction, persistent or worsening bone or muscle symptoms should be evaluated for hypophosphatemia and osteomalacia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Tenofovir disoproxil fumarate may cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID use). Acute renal failure has occurred in HIV-infected patients with risk factors for renal impairment who were on a stable tenofovir regimen to which a high dose or multiple NSAID therapy was added. Consider alternatives to NSAIDS in patients taking tenofovir disoproxil fumarate and at risk for renal impairment. Calculate creatinine clearance prior to initiation of therapy and as clinically appropriate during therapy. In patients at risk for renal dysfunction, including patients who have experienced renal events while taking adefovir, assess serum phosphorus, urine glucose, and urine protein prior to and periodically during treatment. IDSA guidelines recommend discontinuing tenofovir (and substituting with alternative antiretroviral therapy) in HIV-infected patients who develop a decline in GFR (a &gt;25% decrease in GFR from baseline and to a level of &lt;60 mL/minute/1.73 m<sup>2</sup>) during use, particularly in presence of proximal tubular dysfunction (eg, euglycemic glycosuria, increased urinary phosphorus excretion and hypophosphatemia, proteinuria [new onset or worsening]) (IDSA [Lucas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: Safety and efficacy during coinfection of HIV and HBV have not been established; acute, severe exacerbations of HBV have been reported following discontinuation of antiretroviral therapy.</b> <b>Not approved for the treatment of chronic hepatitis B virus infection.</b> <b> Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue this therapy. If appropriate, anti-hepatitis B therapy may be warranted.</b> All patients with HIV should be tested for HBV prior to initiation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Comprehensive prevention program: Preexposure prophylaxis (PrEP) should be accompanied by a comprehensive HIV-1 prevention program (eg, risk reduction counseling, access to condoms), with particular emphasis on medication adherence. In addition, regular monitoring (eg, HIV status of patient and partner(s), risk behavior, adherence, adverse effects, sexually transmitted infections that facilitate HIV-1 transmission) is highly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV treatment: Appropriate use: Not recommended as a component of a triple nucleoside regimen due to potential for early virological failure. Clinical trials in HIV-infected patients whose regimens contained only three nucleoside reverse transcriptase inhibitors (NRTI) show less efficacy, early virologic failure and high rates of resistance substitutions. Triple drug regimens with two NRTIs in combination with a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor are usually more effective.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV treatment and renal impairment: Use with caution in patients with renal impairment (CrCl &lt;50 mL/minute); dosage adjustment required. Closely monitor renal function and assess serum phosphorus, urine glucose, and urine protein prior to and periodically during treatment. Do not use in patients with CrCl &lt;30 mL/minute or requiring hemodialysis. IDSA guidelines recommend avoiding tenofovir in HIV patients with preexisting kidney disease (CrCl &lt;50 mL/minute and not on hemodialysis or GFR &lt;60 mL/minute/1.73 m<sup>2</sup>) when other effective HIV treatment options exist because data suggest risk of chronic kidney disease (CKD) is increased (IDSA [Lucas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; PrEP and renal impairment: Routinely monitor serum phosphorus, urine glucose, and urine protein prior to and periodically during treatment in patients with mild renal impairment. Do not use in CrCl &lt;60 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance risk with PrEP: <b>[US Boxed Warning]: Confirm HIV-1 negative status immediately before and at least every 3 months during therapy.</b> <b>Do not start PrEP if signs or symptoms of acute HIV-1 infection are present unless HIV-1 negative status is confirmed</b> by a test approved by the Food and Drug Administration (FDA) as an aid to detect HIV-1 infection (including acute or primary infection). <b>Risk of drug resistant HIV-1 variants with PrEP use if patient had undetected acute HIV-1 infection.</b> Some HIV-1 tests (eg, rapid tests) do not detect acute HIV-1 infection. Screen PrEP candidates for acute viral infections and potential exposure events within 1 month of starting PrEP. If infections or events exist, wait 1 month to start PrEP and reconfirm HIV-1 negative status. If symptoms consistent with acute HIV-1 infection develop following a potential exposure during PrEP, discontinue PrEP until negative infection status is confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duplicate therapy: Do not use concurrently with emtricitabine, lamivudine, tenofovir disoproxil fumarate, tenofovir alafenamide, or any combination of these drugs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26114990\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Emtricitabine-associated hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults (children: 32%; adults: 2% to 6%).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Recent studies suggest that tenofovir-related bone loss may be greater in children who are less mature (eg, Tanner stage 1-2) than in those who are more physically mature (Tanner &ge;3). A significant decrease in lumbar spine BMD (&gt;6%) was reported in five of 15 pediatric patients who received a tenofovir-containing regimen for 48 weeks. No orthopedic fractures occurred, but two patients required discontinuation of tenofovir. All five patients with a decrease in BMD were virologic responders and prepubertal (Tanner Stage 1). This study found a moderately strong correlation between decreases in bone mineral density z scores at week 48 and age at baseline. No correlation between decreases in bone mineral density z scores and tenofovir dose or pharmacokinetics was observed; BMD loss may limit the usefulness of tenofovir in prepubertal children (Giacomet 2005; Hazra 2005; Purdy 2008). Monitor BMD for potential bone toxicities during therapy; supplementation with calcium and vitamin D may be beneficial but has not been studied. <b>Note:</b> The sexual maturity rating (SMR) has replaced Tanner staging to identify puberty stages in adolescent patients (HHS [pediatric] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299259\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164664\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13013&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adefovir: May diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.  Management: Must use ritonavir-boosting in adults; give combo (atazanavir/ritonavir 300mg/100mg and tenofovir 300mg) as a single daily dose with food.  Pediatric patients, pregnant patients, and users of H2-blockers require other dose changes.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cidofovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May enhance the adverse/toxic effect of Tenofovir Products. More specifically, cobicistat may impair proper tenofovir monitoring and dosing.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: Tenofovir Disoproxil Fumarate may increase the serum concentration of Darunavir. Darunavir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to this combination whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Tenofovir Disoproxil Fumarate may diminish the therapeutic effect of Didanosine. Tenofovir Disoproxil Fumarate may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir disoproxil fumarate and didanosine.  Consider altering even existing, stable treatment to avoid this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: May increase the serum concentration of Tenofovir Disoproxil Fumarate. Management: Avoidance of this combination is recommended under some circumstances.  Refer to full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May enhance the nephrotoxic effect of Tenofovir Disoproxil Fumarate. Lopinavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: May increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164679\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164666\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164675\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines consider emtricitabine with tenofovir disoproxil fumarate to be a preferred NRTI backbone for initial therapy in antiretroviral-naive pregnant females. Emtricitabine with tenofovir disoproxil fumarate is also recommended as part of a regimen when acute HIV infection is detected during pregnancy. In general, females who become pregnant on a stable antiretroviral therapy (ART) regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The HHS perinatal guidelines also recommend emtricitabine plus tenofovir disoproxil fumarate as a component of regimens for HIV/HBV-coinfected pregnant females.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In addition, this combination is recommended for pre-exposure prophylaxis in couples with differing HIV status who are planning a pregnancy. The partner without HIV should begin therapy 1 month prior to and continue for 1 month after conception is attempted (HHS [perinatal] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Refer to individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010727\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>HIV treatment: Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients should be screened for hepatitis B infection before starting therapy. Prior to initiation of therapy: HIV genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, urine dipstick for protein and glucose, electrolytes, glucose, urinalysis (every 6 to 12 months), hepatitis B screening (if previously demonstrated no immunity to hepatitis B), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: Hepatitis B screening, CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Every 6 to 12 months: Lipid panel and urinalysis. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, lactic acidosis, hyperpigmentation, or bone abnormalities. Consider bone mineral density assessment for all patients with a history of pathologic bone fractures or other risk factors for osteoporosis or bone loss. Some experts recommend obtaining a DXA scan prior to therapy and 6 months into therapy, especially for patients in pre- and early puberty (Sexual Maturity Rating 1 and 2) (HHS [pediatric] 2017). In patients coinfected with HBV, monitor hepatic function closely (clinically and with laboratory tests) for at least several months after discontinuing emtricitabine and tenofovir therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>HIV-1 pre-exposure prophylaxis (PrEP):</b> Pregnancy test for women receiving PrEP (every visit); documented negative HIV test (immediately prior to use, every 2 to 3 months, and following discontinuation of PrEP), assess risk behaviors and symptoms of sexually transmitted infections (STIs) or acute HIV-1 infection and provide condoms (immediately prior to use, then every 2 to 3 months during therapy); BUN and serum creatinine (prior to initiation, 3 months after initiation, then every 6 months); testing for HBV (prior to initiation) and STIs (prior to initiation, then at least every 6 months, even if asymptomatic) (CDC 2011; CDC 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164660\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nucleoside and nucleotide reverse transcriptase inhibitor combination; emtricitabine is a cytosine analogue while tenofovir is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164673\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16057338\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Emtricitabine is the (-) enantiomer of 2', 3'-dideoxy-5-fluoro-3'-thiacytidine (FTC), a fluorinated derivative of lamivudine.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Mutation in the HIV reverse transcriptase gene at codon 184, M184V/I (ie, substitution of methionine by valine or isoleucine) is associated with resistance to emtricitabine. Emtricitabine-resistant isolates (M184V/I) are cross-resistant to lamivudine and zalcitabine. HIV-1 isolates containing the K65R mutation show reduced susceptibility to emtricitabine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422225\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Truvada Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100-150 mg (30): $2,010.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">133-200 mg (30): $2,010.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">167-250 mg (30): $2,010.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-300 mg (30): $2,010.95</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301432\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Emtifovir (BD);</li>\n      <li>Emzavir (LB);</li>\n      <li>Fovirem (CO);</li>\n      <li>Recovir-Em (TH);</li>\n      <li>Teno-Em (TH);</li>\n      <li>Tenvir EM (UY);</li>\n      <li>Tenvir-EM (IN);</li>\n      <li>Tenvor-Em (LB);</li>\n      <li>Tolak E (CO);</li>\n      <li>Trenstad (VN);</li>\n      <li>Truvada (AE, AR, AT, AU, BB, BE, BG, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, JO, JP, KR, LT, LU, LV, MT, MX, NI, NL, NO, NZ, PA, PL, PT, RO, RU, SE, SG, SI, SK, SV, TH, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(31):586-589.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/22874836/pubmed\" target=\"_blank\" id=\"22874836\">22874836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. <i>MMWR Morb Mortal Wkly Rep</i>. 2011;60(3):65-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/21270743/pubmed\" target=\"_blank\" id=\"21270743\">21270743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services. April 8, 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Accessed November 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Updated Guidelines for Antiretroviroal Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. Available at <a href=\"https://stacks.cdc.gov/view/cdc/38856\" target=\"_blank\">https://stacks.cdc.gov/view/cdc/38856</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigan&ograve; A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. <i>J Acquir Immune Defic Syndr</i>. 2005;40(4):448-450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/16280700/pubmed\" target=\"_blank\" id=\"16280700\">16280700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. <i>Pediatrics</i>. 2005;116(6):e846-e854.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/16291735/pubmed\" target=\"_blank\" id=\"16291735\">16291735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9):e96-138.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. <i>J Pediatr</i>. 2008;152(4):582-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/18346519/pubmed\" target=\"_blank\" id=\"18346519\">18346519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Truvada (emtricitabine/tenofovir) [prescribing information]. Foster City, CA: Gilead Sciences; April 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13013 Version 161.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708729\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F164681\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2934286\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1010698\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1010720\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164669\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F164659\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F14633101\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1010725\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F164678\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1010699\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708023\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164699\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164674\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F164661\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26114990\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299259\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F164664\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F164679\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F164666\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F164675\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1010727\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F164660\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F164673\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F16057338\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422225\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301432\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13013|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate and emtricitabine: Drug information</a></li><li><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-patient-drug-information\" class=\"drug drug_patient\">Tenofovir disoproxil fumarate and emtricitabine: Patient drug information</a></li></ul></div></div>","javascript":null}